News
Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...
16h
ScienceAlert on MSNNew Weight Loss Drug Outperformed Existing Treatment in Clinical Trial
Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...
“Most users tolerate GLP-1 medications like Ozempic without serious oral health issues, but a subset experience notable side ...
7h
WISH-TV on MSNFDA-approved semaglutide aids weight loss and health conditions
Learn about the use of GLP-1 agonists for weight loss and health improvement by celebrities like Oprah and Serena Williams.
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
8d
MedPage Today on MSNSemaglutide Gets FDA Greenlight for MASH
The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic ...
Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...
Dentists claim weight-loss drugs could majorly impact users' saliva glands, helping gum disease to fester in their mouths.
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results